Clinical Trial Update: Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating semapimod for moderate to severe Crohn's disease compared to placebo has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Semapimod (CNI-1493)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED